Skip to content
DataLookout
Menu

PRoHerpARDNCT07341386

Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved at least 8 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Apr 1, 2027 to Dec 20, 2027
    • Eligibility criteria expanded, about 5 words
    • Secondary endpoints: details revised at 11 of 18 entries
    • Publications: details revised at 3 of 3 entries
  2. Notable Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 1, 2026 to Jun 25, 2026
    v3
  3. Notable Start date: Jan 5, 2026 to Apr 1, 2026v2 Show 4 more changesShow less
    • Eligibility criteria shortened, about 7 words
    • Primary completion date: Dec 1, 2027 to Apr 1, 2027
    • Study completion date: Mar 1, 2028 to Apr 1, 2028
    • Secondary endpoints: details revised at 1 of 18 entries
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

HSV Reactivation Rate
Timeframe: Baseline to Month 24

Secondary (18)

Safety Profile - Adverse Events (AEs)
Frequency of Serious Adverse Events (SAEs)
Treatment Discontinuation Due to AEs
Time to First HSV Reactivation
Factors Associated with HSV Reactivation
Show 13 moreShow less
Disease Activity Flares - Systemic Lupus Erythematosus
Disease Activity Flares - Rheumatoid Arthritis
Disease Activity Flares - Juvenile Idiopathic Arthritis
Disease Activity Flares - Ankylosing Spondylitis
Disease Activity Flares - Psoriatic Arthritis
Disease Activity Flares - Dermatomyositis/Polymyositis
Disease Activity Flares - Systemic Sclerosis
Disease Activity Flares - Systemic Vasculitis
Disease Activity Flares - Primary Sjögren's Syndrome
Disease Activity Flares - Mixed Connective Tissue Disease
Disease Activity Flares - Chronic Recurrent Multifocal Osteomyelitis
Disease Activity Flares - Sarcoidosis
Disease Activity Flares - Behçet's Syndrome

Arms and interventions

ACVActive comparator

Patients with autoimmune rheumatic diseases and a history of recurrent HS will receive oral acyclovir 400 mg twice a day for 12 months. ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: ACV or Placebo.

PlaceboPlacebo comparator

Patients with autoimmune rheumatic diseases and a history of recurrent HS will receive oral placebo twice a day for 12 months. ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: ACV or Placebo.

Drugs: Acyclovir (ACV)

Other: Placebo

Sites

1 site in 1 country

  • Reumatology division of Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo 05403-000São Paulo, São Paulo, Brazil